NCT06134414View on ClinicalTrials.gov

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

MY008211A tablets

dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization

All Listed Sponsors
lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY